Source comparison
BPC-157 MK-677 for Long-Term Healing: Protocol Comparison
Primary Mechanism VEGF upregulation, fibroblast migration, localized angiogenesis GH/IGF-1 elevation, systemic anabolic signaling, nitrogen retention Dual-pathway: localized tissue repair + systemic hormonal support Combined protocol addresses both local injur
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF upregulation, fibroblast migration, localized angiogenesis
- GH/IGF-1 elevation, systemic anabolic signaling, nitrogen retention
- Dual-pathway: localized tissue repair + systemic hormonal support
- Combined protocol addresses both local injury and systemic recovery environment. Synergistic rather than redundant
- Typical Dosing
- 250–500 μg daily, subcutaneous near injury site
- 10–25 mg daily, oral administration before sleep
- 250 μg BPC-157 + 12.5–25 mg MK-677 daily
- Split dosing allows independent timing: BPC-157 post-injury, MK-677 pre-sleep for GH pulse
- Timeline to Measurable Effect
- Subjective pain reduction 7–10 days; imaging-confirmed tissue remodeling 3–4 weeks
- IGF-1 elevation within 14 days; bone density changes require 6–12 months
- Acute inflammation resolution 10–14 days; functional strength recovery 6–8 weeks
- Combined timeline reflects layered repair: vascular phase (weeks 1–3), remodeling phase (weeks 4–12)
- Primary Application
- Acute soft tissue injuries, tendinopathy, ligament strain, surgical recovery
- Bone density preservation, muscle wasting prevention, age-related GH decline
- Chronic injuries requiring both tissue regeneration and systemic anabolic environment
- Best suited for injuries where single-agent protocols plateau. Chronic tendinopathy, failed surgical outcomes, elderly patients
- Known Limitations
- Minimal human clinical trial data; dosing extrapolated from animal models
- Water retention, transient insulin resistance, appetite stimulation in 30–40% of users
- Requires management of MK-677 side effects alongside BPC-157 administration; cost significantly higher than monotherapy
- MK-677's metabolic side effects (fasting glucose elevation, edema) require monitoring; BPC-157 lacks FDA oversight. All use is off-label research